Biocept shares are trading higher after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics.
Portfolio Pulse from Benzinga Newsdesk
Biocept has entered into a non-exclusive licensing agreement for CNSide with Plus Therapeutics. This news has led to an increase in Biocept's share prices.
September 08, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biocept's stock price is rising after the announcement of a non-exclusive licensing agreement with Plus Therapeutics for CNSide.
The non-exclusive licensing agreement with Plus Therapeutics for CNSide is a positive development for Biocept. This partnership could potentially lead to increased revenues for Biocept, which is likely why the stock price has increased.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100